2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Hematologists’ barriers and enablers to screening and recruiting patients to a chimeric antigen receptor (CAR) T cell therapy trial: a theory-informed interview study

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Novel therapies often fail to reach the bedside due to low trial recruitment rates. Prior to conducting one of the first chimeric antigen receptor (CAR) T cell therapy trials in Canada, we used the Theoretical Domains Framework, a novel tool for identifying barriers and enablers to behavior change, to identify physician-related barriers and enablers to screening and recruiting patients for an early phase immunotherapy trial.

          Methods

          We conducted interviews with hematologists across Canada and used a directed content analysis to identify relevant domains reflecting the key factors that may affect screening and recruitment.

          Results

          In total, we interviewed 15 hematologists. Physicians expressed “cautious hope”; while expressing safety, feasibility, and screening criteria concerns, 14 out of 15 hematologists intended to screen for the trial (domains: knowledge, goals, beliefs about consequences, intentions). Physicians underscored the “challenging contexts,” identifying resources, workload, forgetting, and patient wait times to receive CAR T cells as key practical barriers to screening (domains: environmental context and resources, memory, attention and decision-making, behavioral regulation). They also highlighted “variability in roles and procedures” that may lead to missed trial candidates (domain: social and professional role). Left unaddressed, these barriers may undermine trial recruitment.

          Conclusions

          This study is among the first to use the Theoretical Domains Framework from the physician perspective to identify recruitment challenges to early phase trials and demonstrates the value of this approach for identifying barriers to screening and recruitment that may not otherwise have been elicited. This approach can optimize trial procedures and may serve to inform future promising early phase cancer therapy trials.

          Trial registration

          ClinicalTrials.gov Identifier: NCT03765177. Registered on December 5, 2018.

          Supplementary Information

          The online version contains supplementary material available at 10.1186/s13063-021-05121-y.

          Related collections

          Most cited references50

          • Record: found
          • Abstract: not found
          • Article: not found

          Using thematic analysis in psychology

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Three approaches to qualitative content analysis.

            Content analysis is a widely used qualitative research technique. Rather than being a single method, current applications of content analysis show three distinct approaches: conventional, directed, or summative. All three approaches are used to interpret meaning from the content of text data and, hence, adhere to the naturalistic paradigm. The major differences among the approaches are coding schemes, origins of codes, and threats to trustworthiness. In conventional content analysis, coding categories are derived directly from the text data. With a directed approach, analysis starts with a theory or relevant research findings as guidance for initial codes. A summative content analysis involves counting and comparisons, usually of keywords or content, followed by the interpretation of the underlying context. The authors delineate analytic procedures specific to each approach and techniques addressing trustworthiness with hypothetical examples drawn from the area of end-of-life care.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

              In a phase 1 trial, axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with refractory large B-cell lymphoma after the failure of conventional therapy.
                Bookmark

                Author and article information

                Contributors
                jpresseau@ohri.ca
                Journal
                Trials
                Trials
                Trials
                BioMed Central (London )
                1745-6215
                25 March 2021
                25 March 2021
                2021
                : 22
                : 230
                Affiliations
                [1 ]GRID grid.412687.e, ISNI 0000 0000 9606 5108, Clinical Epidemiology Program, , Ottawa Hospital Research Institute, ; 501 Smyth Road, Ottawa, Ontario K1H 8L6 Canada
                [2 ]GRID grid.412687.e, ISNI 0000 0000 9606 5108, Blueprint Translational Research Group, , Ottawa Hospital Research Institute, ; 501 Smyth Road, Ottawa, Ontario K1H 8L6 Canada
                [3 ]GRID grid.28046.38, ISNI 0000 0001 2182 2255, Department of Anaesthesiology and Pain Medicine, , University of Ottawa at the Ottawa Hospital General Campus, ; 501 Smyth Road, Ottawa, Ontario K1H 8L6 Canada
                [4 ]GRID grid.412687.e, ISNI 0000 0000 9606 5108, Blood and Marrow Transplant Program, , The Ottawa Hospital, ; 501 Smyth Road, Ottawa, Ontario K1H 8L6 Canada
                [5 ]GRID grid.28046.38, ISNI 0000 0001 2182 2255, School of Epidemiology and Public Health, , University of Ottawa, ; 600 Peter Morand Crescent, Ottawa, Ontario K1G 5Z3 Canada
                [6 ]Patient Partners, Ottawa, Canada
                [7 ]GRID grid.28046.38, ISNI 0000 0001 2182 2255, Institute for Clinical and Evaluative Sciences (ICES), , University of Ottawa, ; 1053 Carling Ave., Ottawa, Ontario K1Y 4E9 Canada
                [8 ]GRID grid.434706.2, ISNI 0000 0004 0410 5424, BC Cancer Genome Sciences Centre, ; 100-570 West 7th Avenue, Vancouver, British Columbia V5Z 4S6 Canada
                [9 ]GRID grid.412541.7, ISNI 0000 0001 0684 7796, Leukemia/BMT Program, , Vancouver General Hospital, ; 2775 Laurel St - 10th floor, Vancouver, British Columbia V5Z 1M9 Canada
                Author information
                http://orcid.org/0000-0002-2132-0703
                Article
                5121
                10.1186/s13063-021-05121-y
                7995587
                33766105
                49e04802-3a74-49d7-a4ff-a47612ecc265
                © The Author(s) 2021

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                History
                : 19 May 2020
                : 11 February 2021
                Funding
                Funded by: BioCanRx
                Award ID: FY17/ CSEI4
                Award Recipient :
                Categories
                Research
                Custom metadata
                © The Author(s) 2021

                Medicine
                chimeric antigen receptor t cell therapy,physician screening,barriers to trial recruitment,theoretical domains framework,early phase clinical trials,early phase immunotherapy trials

                Comments

                Comment on this article